title: Human cytomegalovirus load in various body fluids of congenitally infected newborns.
abstract: BACKGROUND
  Congenital human cytomegalovirus (hCMV) infection is the most common intrauterine viral disease in western countries. Little is known about hCMV virus load in various body fluids of congenitally infected children.
  
  
  OBJECTIVE
  To determine virus load in various body fluids. To assess the impact of hCMV virus load to predict the outcome of congenitally infected newborns and efficacy of antiviral therapy.
  
  
  METHODS
  Cord vein blood, urine, and cerebrospinal fluid (CSF) of congenitally hCMV-infected children were investigated and hCMV load was determined by quantitative polymerase chain reaction (PCR). Fourteen of 30 children had clinical symptoms and/or pathological laboratory results and 16 had none of them at birth. Ganciclovir was given to 21 children (10 of them with symptoms, 11 of them without symptoms). Viral load before and after therapy was measured.
  
  
  RESULTS
  There was a significant difference between median virus load in cord vein blood (2.3 x 10(3) copies per ml) and in urine (4.2 x 10(5) copies per ml; P<0.001) at diagnosis of congenital hCMV infection. At that time, no significant difference of virus load was found between the various groups (symptomatic vs. asymptomatic; with therapy vs. without therapy), neither in serum nor in urine. Comparing median virus load in urine before (3.0 x 10(5) copies per ml) and after therapy (2.0 x 10(3) copies per ml), a significant decrease was observed (P<0.001). Virus load in CSF was always found to be less than 400 copies per ml, and only those children with symptoms showed a positive result.
  
  
  CONCLUSIONS
  At birth, virus load in urine seems to be superior to that in cord vein blood to reflect the situation in the organs precisely. As predicting factor for the risk of developing symptoms, only hCMV detection in the CSF appears to be promising. The significant decrease of virus load in children with therapy may reflect the efficacy of therapy. Studies including a greater number of children are needed.
authors.affiliation: Department of Clinical Chemistry and Laboratory Medicine, University Hospital Graz, Auenbruggerplatz 29, A-8036 Graz, Austria. gabriele.halwachs@uni-graz.at
authors.forename: Gabriele
authors.initials: G
authors.lastname: Halwachs-Baumann
authors.forename: Bernd
authors.initials: B
authors.lastname: Genser
authors.forename: Sabine
authors.initials: S
authors.lastname: Pailer
authors.forename: Heidi
authors.initials: H
authors.lastname: Engele
authors.forename: Hellfried
authors.initials: H
authors.lastname: Rosegger
authors.forename: Andreas
authors.initials: A
authors.lastname: Schalk
authors.forename: Harald H
authors.initials: HH
authors.lastname: Kessler
authors.forename: Martie
authors.initials: M
authors.lastname: Truschnig-Wilders
mesh_terms: D000956:Antigens, Viral / Q000097:blood; D001826:Body Fluids / Q000821:virology*; D002555:Cerebrospinal Fluid / Q000821:virology; D003587:Cytomegalovirus / Q000276:immunology / Q000302:isolation & purification / Q000502:physiology*; D003586:Cytomegalovirus Infections / Q000097:blood / Q000151:congenital* / Q000517:prevention & control / Q000821:virology; D005312:Fetal Blood / Q000821:virology; D015774:Ganciclovir / Q000627:therapeutic use; D006801:Humans; D015994:Incidence; D007231:Infant, Newborn; D007232:Infant, Newborn, Diseases / Q000821:virology*; D015997:Neonatal Screening; D016133:Polymerase Chain Reaction; D014556:Urine / Q000821:virology; D019562:Viral Load; D014763:Viral Matrix Proteins / Q000097:blood; D014766:Viremia / Q000175:diagnosis
chemical_list: D000956:Antigens, Viral; D014763:Viral Matrix Proteins; D015774:Ganciclovir